Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.
You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback